Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory
multiple myeloma with at least two prior lines of therapy. The main study consists of three
phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of
isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.